Want to see AU:HMD full AI Analyst Report?
HMD Stock Chart & Stats
AU$0.04
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.04
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.06
Previous CloseN/A
Volume370.09K
Average Volume (3M)641.63K
Market Cap
AU$47.50M
Enterprise ValueAU$39.94
Total Cash (Recent Filing)AU$2.03M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Mar 03, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,158,636,600
10 Day Avg. Volume1,383,403
30 Day Avg. Volume641,629
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)41.38
Price to Sales (P/S)131.32
P/FCF Ratio-10.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Gross MarginThe shift to roughly 60% gross margin indicates the company’s offerings have stronger unit economics than in earlier years. If maintained, this creates more contribution from each sale and provides a foundation for future operating leverage, although profitability has not yet followed.
Deleveraged Balance SheetEliminating debt reduces interest and refinancing exposure, giving HeraMED a less leveraged financial structure than in 2021. Positive equity also provides a healthier base for managing operations, though the small and shrinking equity cushion limits the strength of this advantage.
Improving Cash BurnLower cash consumption in 2025 is a constructive directional change because it may extend the company’s operating runway and reduce near-term funding pressure. The improvement is meaningful, but it must become consistent and eventually turn positive to support durable self-funded growth.
Bears Say
Revenue ContractionRecent revenue contraction and historical volatility limit operating leverage and make it harder to spread fixed costs across a growing business. Without a sustained return to top-line expansion, HeraMED may struggle to convert its improved gross margin into stronger earnings and cash generation.
Persistent LossesOngoing operating and net losses show that the current business model has not yet achieved sustainable profitability despite improved gross margins. Continued losses can weaken equity over time, constrain reinvestment capacity, and leave future performance dependent on a successful improvement in operating leverage.
Negative Operating Cash FlowA repeated inability to generate positive operating and free cash flow means the business continues consuming cash to operate. This raises longer-term funding and liquidity pressure, reduces financial flexibility, and makes durable expansion more difficult unless cash conversion improves materially.
HeraMED Ltd. News
HMD FAQ
What was HeraMED Ltd.’s price range in the past 12 months?
HeraMED Ltd. lowest share price was AU$0.03 and its highest was AU$0.06 in the past 12 months.
What is HeraMED Ltd.’s market cap?
HeraMED Ltd.’s market cap is AU$47.50M.
When is HeraMED Ltd.’s upcoming earnings report date?
HeraMED Ltd.’s upcoming earnings report date is Mar 03, 2027 which is in 165 days.
How were HeraMED Ltd.’s earnings last quarter?
HeraMED Ltd. released its earnings results on Aug 21, 2026. The company reported -AU$0.001 earnings per share for the quarter.
Is HeraMED Ltd. overvalued?
According to Wall Street analysts HeraMED Ltd.’s price is currently Overvalued.
Does HeraMED Ltd. pay dividends?
HeraMED Ltd. does not currently pay dividends.
What is HeraMED Ltd.’s EPS estimate?
HeraMED Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HeraMED Ltd. have?
HeraMED Ltd. has 1,158,636,600 shares outstanding.
What happened to HeraMED Ltd.’s price movement after its last earnings report?
HeraMED Ltd. reported an EPS of -AU$0.001 in its last earnings report. Following the earnings report the stock price went up 2.703%.
Which hedge fund is a major shareholder of HeraMED Ltd.?
Currently, no hedge funds are holding shares in AU:HMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HeraMED Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
15.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
114.27%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
HeraMED Ltd.
HeraMED Limited and its associated entities are dedicated to the design, production, and sale of at-home fetal heart rate monitors and comprehensive pregnancy monitoring systems. These solutions are offered to consumers throughout Australia, Europe, and Israel. Key products include HeraBEAT, a device enabling expectant mothers to personally track their baby's heartbeat, and HeraCARE, a sophisticated digital platform facilitating the creation and deployment of health solutions for effective maternity care management. The company is also at the forefront of developing EchoBEAT, envisioned as the subsequent evolution of its domestic pregnancy monitoring tools, alongside Orion, an artificial intelligence-driven system engineered for profound pregnancy monitoring analysis. A strategic partnership with Mayo Clinic supports the ongoing advancement of the HeraCARE pregnancy management platform. Established in 2011, HeraMED Limited operates from its main office in Netanya, Israel.
Technical Analysis
Compumedics Limited
―
Impedimed Limited
―
Uscom Limited
―
Atomo Diagnostics Ltd.
―
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
―